FOXO Technologies Inc. FOXO

FOXO Company Overview

FOXO Technologies Inc. (NYSE American: FOXO) is a biotechnology and technology-focused company that has operated in the longevity science, epigenetics, and health data analytics sectors. The company became publicly traded through a business combination involving a special purpose acquisition company (SPAC) in 2022. FOXO’s historical business strategy centered on developing commercial applications for epigenetic biomarkers and longevity-related analytics intended for use in life insurance underwriting, healthcare engagement, and population health management.

The company’s primary business activities have included biological age testing, epigenetic data analysis, and technology-enabled health and insurance solutions. FOXO has also pursued acquisitions and investments intended to diversify its operating model beyond core longevity biotechnology. Public filings and investor materials indicate that the company sought to position itself at the intersection of biotechnology, insurance technology, and data-driven healthcare services. However, publicly available disclosures also indicate operational restructuring, financial constraints, and evolving strategic priorities in recent years. Certain aspects of the company’s long-term commercial execution remain difficult to independently verify due to changing corporate disclosures and limited scale of reported operations.